Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • When should systemic biologic...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
When should systemic biologic therapy for psoriasis be discontinued?

When should systemic biologic therapy for psoriasis be discontinued?

Bibliographic Details
Main Authors: Diem-Phuong D. Dao, Jessica N. Pixley, Steven R. Feldman
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Journal of Dermatological Treatment
Online Access:http://dx.doi.org/10.1080/09546634.2023.2173516
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://dx.doi.org/10.1080/09546634.2023.2173516

Similar Items

  • Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?
    by: Joeseph Nenow, et al.
    Published: (2021-11-01)
  • Could red and near-infrared emitting fabric technology improve the severity of psoriasis, polymorphous light eruption, and alopecia areata?
    by: Jessica N. Pixley, et al.
    Published: (2023-12-01)
  • Racial differences in access to psoriasis biologics
    by: Shirley P. Parraga, et al.
    Published: (2024-12-01)
  • Management of Pediatric Psoriasis: A U.S. Survey Based on Visits from the National Ambulatory Medical Care Survey (NAMCS)
    by: Rachel E. Tao, et al.
    Published: (2023-10-01)
  • The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?
    by: Rafael Denadai, et al.
    Published: (2012-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs